From 11:00 pm to 12:00 pm EST ( 8:00 pm to 9:00 pm PST ) on January 6th, the website will be under maintenance. We are sorry for the inconvenience. Please arrange your schedule properly.
Cyclopropaneacetamide-Exatecan (Compound 2-A) is an ADC Cytotoxin and an Exatecan analogue. Cyclopropaneacetamide-Exatecan can be used in the synthesis of ADC such as anti-B7H3 antibody-Exatecan analogue conjugate (compound ADC-2) .
Vobramitamab is a humanized B7-H3 monoclonal antibody (mAb). Vobramitamab conjugated with prodrug seco-DUBA (HY-132180A) via a cleavable linker, to form antibody-drug conjugate (ADC), the MGC018 .
Obrindatamab is a humanized anti-B7-H3/CD3 bispecific antibody. Obrindatamab binds to B7-H3 and CD3, thereby mediating redirected cytotoxic T-lymphocyte (CTL) activity against B7-H3-expressing cancer cells. Obrindatamab can be used in research of cancer .
FDW028 a potent and highly selective FUT8 inhibitor. FUT8 exhibits potent anti-tumor activity by defucosylation and impelling lysosomal degradation of B7-H3 through the chaperone-mediated autophagy (CMA) pathway. FDW028 can be used for metastatic colorectal cancer (mCRC) research .
Omburtamab is an anti-CD276 (also known as B7-H3) monoclonal antibody, CD276 is a B7/CD28 immunoglobulin superfamily member expressed among solid human tumours. Omburtamab can bind tumor tissues and be used in various cancers research .
Lacnotuzumab (MCS110) is a neutralizing humanized IgG1/κ monoclonal antibody targeting CSF-1 that prevents CSF-1 from activating the CSF-1R. Lacnotuzumab can be used for the research of pigmented villonodular synovitis .
Mirzotamab is an IgG1κ antibody targeting to CD276/B7-H3. Mirzotamab can conjugates with Clezutoclax (HY-137774), an BCL inhibitor to form Mirzotamab clezutoclax (HY-P99741), involving in research with taxane research in relapsed/refractory solid tumors. Mirzotamab clezutoclax (ABBV-155) is a targeted antibody drug conjugate (ADC) .
Vobramitamab is a humanized B7-H3 monoclonal antibody (mAb). Vobramitamab conjugated with prodrug seco-DUBA (HY-132180A) via a cleavable linker, to form antibody-drug conjugate (ADC), the MGC018 .
Obrindatamab is a humanized anti-B7-H3/CD3 bispecific antibody. Obrindatamab binds to B7-H3 and CD3, thereby mediating redirected cytotoxic T-lymphocyte (CTL) activity against B7-H3-expressing cancer cells. Obrindatamab can be used in research of cancer .
Omburtamab is an anti-CD276 (also known as B7-H3) monoclonal antibody, CD276 is a B7/CD28 immunoglobulin superfamily member expressed among solid human tumours. Omburtamab can bind tumor tissues and be used in various cancers research .
Lacnotuzumab (MCS110) is a neutralizing humanized IgG1/κ monoclonal antibody targeting CSF-1 that prevents CSF-1 from activating the CSF-1R. Lacnotuzumab can be used for the research of pigmented villonodular synovitis .
Mirzotamab is an IgG1κ antibody targeting to CD276/B7-H3. Mirzotamab can conjugates with Clezutoclax (HY-137774), an BCL inhibitor to form Mirzotamab clezutoclax (HY-P99741), involving in research with taxane research in relapsed/refractory solid tumors. Mirzotamab clezutoclax (ABBV-155) is a targeted antibody drug conjugate (ADC) .
CD276/B7-H3 protein can regulate T cell-mediated immune responses and act as a protective factor for tumor cells by inhibiting natural killer-mediated cell lysis. It also functions as a neuroblastoma cell marker, plays a role in acute and chronic transplant rejection, and modulates lymphocyte activity at mucosal surfaces. FITC-Labeled CD276/B7-H3 Protein, Human (435a.a, HEK293, Fc) is the recombinant human-derived FITC-Labeled CD276/B7-H3 protein, expressed by HEK293 , with Fc labeled tag. The total length of FITC-Labeled CD276/B7-H3 Protein, Human (435a.a, HEK293, Fc) is 435 a.a., with molecular weight of 95-115 kDa.
CD276/B7-H3 protein can regulate T cell-mediated immune responses and act as a protective factor for tumor cells by inhibiting natural killer-mediated cell lysis. It also functions as a neuroblastoma cell marker, plays a role in acute and chronic transplant rejection, and modulates lymphocyte activity at mucosal surfaces. CD276/B7-H3 Protein, Human (Biotinylated, HEK293, His-Avi) is the recombinant human-derived CD276/B7-H3 protein, expressed by HEK293 , with C-Avi, C-His labeled tag. The total length of CD276/B7-H3 Protein, Human (Biotinylated, HEK293, His-Avi) is 435 a.a., with molecular weight of 70-80 kDa.
CD276/B7-H3 Protein may regulate T-cell-mediated immune responses, acting as a protective factor in tumor cells by inhibiting natural-killer-mediated cell lysis. It also serves as a neuroblastoma cell marker and plays a role in acute and chronic transplant rejection, regulating lymphocytic activity at mucosal surfaces. Crucially, CD276/B7-H3 may provide an immunologically suitable environment for the placenta and fetus during pregnancy. Both isoforms modulate CD4 T-cell responses, with isoform 2 enhancing cytotoxic T-cells and selectively stimulating interferon-gamma production. Interaction with TREML2 enhances T-cell activation, highlighting CD276/B7-H3's diverse roles in immune regulation and cellular responses. CD276/B7-H3 Protein, Human (Biotinylated, HEK293, Fc-Avi) is the recombinant human-derived CD276/B7-H3 protein, expressed by HEK293, with C-Avi, C-hFc labeled tag. The total length of CD276/B7-H3 Protein, Human (Biotinylated, HEK293, Fc-Avi) is 217 a.a., with molecular weight of 63-70 kDa.
CD276/B7-H3 Protein, Human (HEK293, Fc) is a polypeptide chain containing the C-termimal His tag produced in HEK293 cells. B7-H3 is an immune checkpoint from the B7 family of molecules.
CD276/B7-H3 Protein may regulate T-cell-mediated immune responses, acting as a protective factor in tumor cells by inhibiting natural-killer-mediated cell lysis. It also serves as a neuroblastoma cell marker and plays a role in acute and chronic transplant rejection, regulating lymphocytic activity at mucosal surfaces. Crucially, CD276/B7-H3 may provide an immunologically suitable environment for the placenta and fetus during pregnancy. Both isoforms modulate CD4 T-cell responses, with isoform 2 enhancing cytotoxic T-cells and selectively stimulating interferon-gamma production. Interaction with TREML2 enhances T-cell activation, highlighting CD276/B7-H3's diverse roles in immune regulation and cellular responses. CD276/B7-H3 Protein, Human (HEK293, His-Avi) is the recombinant human-derived CD276/B7-H3 protein, expressed by HEK293, with C-Avi, C-His labeled tag. The total length of CD276/B7-H3 Protein, Human (HEK293, His-Avi) is 435 a.a., with molecular weight of 70-80 kDa.
CD276/B7-H3 protein can regulate T cell-mediated immune responses and act as a protective factor for tumor cells by inhibiting natural killer-mediated cell lysis. It also functions as a neuroblastoma cell marker, plays a role in acute and chronic transplant rejection, and modulates lymphocyte activity at mucosal surfaces. CD276/B7-H3 Protein, Cynomolgus (437a.a, HEK293, Fc) is the recombinant cynomolgus-derived CD276/B7-H3 protein, expressed by HEK293 , with C-hFc labeled tag. The total length of CD276/B7-H3 Protein, Cynomolgus (437a.a, HEK293, Fc) is 437 a.a., with molecular weight of 100-123 kDa.
CD276/B7-H3 protein can regulate T cell-mediated immune responses and act as a protective factor for tumor cells by inhibiting natural killer-mediated cell lysis. It also functions as a neuroblastoma cell marker, plays a role in acute and chronic transplant rejection, and modulates lymphocyte activity at mucosal surfaces. CD276/B7-H3 Protein, Cynomolgus (437a.a, HEK293, His) is the recombinant cynomolgus-derived CD276/B7-H3 protein, expressed by HEK293 , with C-6*His labeled tag. The total length of CD276/B7-H3 Protein, Cynomolgus (437a.a, HEK293, His) is 437 a.a., with molecular weight of 70-95 kDa.
CD276/B7-H3 Protein, Human (HEK293, His) is a polypeptide chain containing the C-termimal His tag produced in HEK293 cells. B7-H3 is an immune checkpoint from the B7 family of molecules.
CD276/B7-H3 Protein may regulate T-cell-mediated immune responses, acting as a protective factor in tumor cells by inhibiting natural-killer-mediated cell lysis. It also serves as a neuroblastoma cell marker and plays a role in acute and chronic transplant rejection, regulating lymphocytic activity at mucosal surfaces. Crucially, CD276/B7-H3 may provide an immunologically suitable environment for the placenta and fetus during pregnancy. Both isoforms modulate CD4 T-cell responses, with isoform 2 enhancing cytotoxic T-cells and selectively stimulating interferon-gamma production. Interaction with TREML2 enhances T-cell activation, highlighting CD276/B7-H3's diverse roles in immune regulation and cellular responses. CD276/B7-H3 Protein, Human (HEK293, Myc-hFc) is the recombinant human-derived CD276/B7-H3 protein, expressed by HEK293, with C-Myc, C-hFc labeled tag. The total length of CD276/B7-H3 Protein, Human (HEK293, Myc-hFc) is 217 a.a., with molecular weight of 53.4 kDa.
CD276/B7-H3 Protein may regulate T-cell-mediated immune responses, acting as a protective factor in tumor cells by inhibiting natural-killer-mediated cell lysis. It also serves as a neuroblastoma cell marker and plays a role in acute and chronic transplant rejection, regulating lymphocytic activity at mucosal surfaces. Crucially, CD276/B7-H3 may provide an immunologically suitable environment for the placenta and fetus during pregnancy. Both isoforms modulate CD4 T-cell responses, with isoform 2 enhancing cytotoxic T-cells and selectively stimulating interferon-gamma production. Interaction with TREML2 enhances T-cell activation, highlighting CD276/B7-H3's diverse roles in immune regulation and cellular responses. CD276/B7-H3 Protein, Human (Biotinylated, HEK293, C-His-Avi) is the recombinant human-derived CD276/B7-H3 protein, expressed by HEK293, with C-Avi, C-His labeled tag. The total length of CD276/B7-H3 Protein, Human (Biotinylated, HEK293, C-His-Avi) is 217 a.a., with molecular weight of 40-50 kDa.
CD276/B7-H3 protein can regulate T cell-mediated immune responses and act as a protective factor for tumor cells by inhibiting natural killer-mediated cell lysis. It also functions as a neuroblastoma cell marker, plays a role in acute and chronic transplant rejection, and modulates lymphocyte activity at mucosal surfaces. CD276/B7-H3 Protein, Human (217a.a, HEK293, Fc) is the recombinant human-derived CD276/B7-H3 protein, expressed by HEK293 , with C-hFc labeled tag. The total length of CD276/B7-H3 Protein, Human (217a.a, HEK293, Fc) is 217 a.a., with molecular weight of 60-70 kDa.
CD276/B7-H3 protein can regulate T cell-mediated immune responses and act as a protective factor for tumor cells by inhibiting natural killer-mediated cell lysis. It also functions as a neuroblastoma cell marker, plays a role in acute and chronic transplant rejection, and modulates lymphocyte activity at mucosal surfaces. CD276/B7-H3 Protein, Human (Biotinylated, HEK293, His) is the recombinant human-derived CD276/B7-H3 protein, expressed by HEK293 , with C-His labeled tag. The total length of CD276/B7-H3 Protein, Human (Biotinylated, HEK293, His) is 433 a.a., with molecular weight of ~73 kDa.
CD276/B7-H3 protein can regulate T cell-mediated immune responses and act as a protective factor for tumor cells by inhibiting natural killer-mediated cell lysis. It also functions as a neuroblastoma cell marker, plays a role in acute and chronic transplant rejection, and modulates lymphocyte activity at mucosal surfaces. CD276/B7-H3 Protein, Human (HEK293, C-His) is the recombinant human-derived CD276/B7-H3 protein, expressed by HEK293 , with C-His labeled tag. The total length of CD276/B7-H3 Protein, Human (HEK293, C-His) is 433 a.a., with molecular weight of ~68 kDa.
CD276/B7-H3 Protein regulates T-cell-mediated immune responses and transplant rejection. It also promotes bone formation, functioning at the bone-immune interface. Additionally, it activates immune responses against tumors, eliminating them through natural killer cells and CD8 T-cells. Its interaction with TREML2 enhances T-cell activation, highlighting its role in immune regulation. CD276/B7-H3 Protein, Rat (HEK293, Fc) is the recombinant rat-derived CD276/B7-H3 protein, expressed by HEK293 , with C-hFc labeled tag. The total length of CD276/B7-H3 Protein, Rat (HEK293, Fc) is 244 a.a., with molecular weight of ~61 kDa.
CD276/B7-H3 Protein regulates T-cell-mediated immune responses and transplant rejection. It also promotes bone formation, functioning at the bone-immune interface. Additionally, it activates immune responses against tumors, eliminating them through natural killer cells and CD8 T-cells. Its interaction with TREML2 enhances T-cell activation, highlighting its role in immune regulation. CD276/B7-H3 Protein, Rat (HEK293, His) is the recombinant rat-derived CD276/B7-H3 protein, expressed by HEK293 , with C-His labeled tag. The total length of CD276/B7-H3 Protein, Rat (HEK293, His) is 244 a.a., with molecular weight of ~43 kDa.
CD276/B7-H3 protein can regulate T cell-mediated immune responses and act as a protective factor for tumor cells by inhibiting natural killer-mediated cell lysis. It also functions as a neuroblastoma cell marker, plays a role in acute and chronic transplant rejection, and modulates lymphocyte activity at mucosal surfaces. CD276/B7-H3 Protein, Human (433a.a, HEK293, His) is the recombinant human-derived CD276/B7-H3 protein, expressed by HEK293 , with C-6*His labeled tag. The total length of CD276/B7-H3 Protein, Human (433a.a, HEK293, His) is 433 a.a., with molecular weight of 65-90 kDa.
